Kornimate/medical-research-clean huggingface dataset:
study of mrgfus exablate treatment following the neuropathic pain

Conditions: Neuropathic Pain

Summary: the objective of this study is to capture the change in pain intensity, physical/emotional function, and pain impact for patients diagnosed with neuropathic pain who undergo an exablate treatment.

the objectives of this study are to capture the change in pain intensity, physical/emotional function, and pain impact for patients diagnosed with neuropathic pain who undergo an exablate treatment and to capture safety data of the procedure. the safety assessment measure is the incidence and frequency of device and procedure related adverse events (aes) in subjects who undergo an exablate treatment. performance will be measure by assessing the change from baseline to 3 months post exablate treatment for pain intensity defined as a decrease of at least 30% of pain on the numeric rating scale (nrs). assessing the change from baseline to 6-12 months post exablate treatment for pain intensity assessed by using the numeric rating scale (nrs)

Eligibility criteria:
inclusion criteria: * men and women age 30 years or older * subject has diagnosis of "definite" neuropathic pain (grading system iasp-neupsig) * patient has a score of 6 or higher on the numeric rating scale (nrs) * evidence that the subject has tried and failed at least three documented medically supervised treatments (including, but not limited to physical therapy, acupuncture, etc.) and has failed medication treatment from at least two different medication classes * evidence that the subject's pain-related medication regimen is stable 4 weeks prior to the baseline evaluation exclusion criteria: * subject diagnosed with a nociceptive chronic pain syndrome * subject does not agree to participate or is unlikely to participate for the entirety of the study * subject is currently participating in another clinical investigation with an active treatment arm

Keywords: peripheral neuropathic pain trigeminal pain central neuropathic pain mrgfus
utilization of the community popular opinion leader (c-pol) model in alabama

Conditions: Risk Behavior; Sexually Transmitted Diseases

Summary: community members within the treatment city will report: 1)engaging in fewer sexual risk practices; 2)significantly higher condom use; 3) significantly higher rates of std care seeking (including std screening behaviors); 4) fewer having stds in the past 6 months; 5) significantly higher awareness scores regarding syphilis and other stds, as compared with those in the comparison city.

the c-pol in alabama project is and intervention study which sought to impact the health behaviors of community residents who live in zip codes that have high syphilis morbidity. the study is being implemented in birmingham and montgomery with shelter clients. the intervention model used for this study is the popular opinion leader (pol) model, which is effective at reducing new hiv infections. the intent of this study was to determine the effectiveness of a diffusion model (e.g. pol) at reducing syphilis infections in affected communities. for the intervention, community members identified as popular opinion leaders were recruited and trained to share accurate information about syphilis transmission, symptoms, testing, treatment and prevention. prior to intervention implementation and several times after, community members were given a survey and screened for syphilis as well as 2-3 additional stds. during each assessment, cross-sections of the community members were sampled.

Eligibility criteria:
inclusion criteria: * clients who utilized two community homeless shelters in the affected community. the affected community was one that had significant syphilis morbidity at the onset of the study. exclusion criteria: * none

Keywords: risk behavior sexually transmitted diseases
cortical resections in drug resistant epilepsy

Conditions: Epilepsy Surgery; Drug Resistant Epilepsy

Summary: the aim of the study is to evaluate safety and efficacy of epilepsy surgery in the form of cortical resections in patients with refractory epilepsy and to review outcomes of resection procedures in focal epilepsy.

nearly one-third of epilepsy patients are refractory/resistant to medical treatment . refractory or drug-resistant epilepsy is defined as resistance to treatment with two appropriately chosen and tolerated antiepileptic drugs (aed) . nevertheless, epilepsy surgery is an effective alternative treatment for some patients as it suggests seizure freedom . during the past 3 decades, surgery has found more acceptance as an option for drug-resistant epilepsy . developments made in surgical techniques (cortical resections) have significantly increased the effectiveness and safety of these techniques; as such techniques have been demonstrated to improve seizure control/freedom outcomes and enhanced quality of life in patients . neuro imaging developments with the introduction of positron emission tomography (pet), magnetic resonance imaging (mri), functional mri, single-photon emission computed tomography (spect), and magneto encephalography, electroencephalography and neuronavigation have facilitated the presurgical evaluation of patients, thus providing the lesion-directed surgeries more possible , also reducing the number and severity of complications . complications of epilepsy surgery including failure to stop seizures and neuropsychological, psychosocial, or psychiatric impairment are still difficult to define, and there is no universal consensus in this regard . this technique characterized by : • once the epilepsy focus is located by using interpretation and collection of data from functional mri, eeg long term video and clinical findings, the specific surgery involved in treatment is decided on. the type of surgery depends on the location of the seizure focal point. surgeries for epilepsy treatment include, but are not limited to, the following types: temporal lobe resection, ground temporal and extra temporal resection, parietal resection, occipital resection, frontal resection, extra temporal resection.

Eligibility criteria:
inclusion criteria: * all patients with focal epilepsy who are refractory to medical treatment. * patients accept surgical maneuver exclusion criteria: * epileptic patients responding to medical treatment. * patients refusing surgical intervention. * patients unfit for brain surgery. * multi focal or generalized seizures.
optical coherence tomography guided percutaneous coronary intervention for drug-eluting in-stent restenosis

Conditions: CHD - Coronary Heart Disease; Percutaneous Coronary Intervention; In-stent Restenosis

Summary: this study is a prospective, registry trial aimed to compare the clinical and angiographic outcomes of oct-guided and angiography-guided pci in patients with coronary des-isr.


Eligibility criteria:
inclusion criteria: * age 18 years or older * patients with angina or evidence of myocardial ischaemia * patients with restenotic lesions in a previously des area of a coronary artery * patients suitable to receive any types of percutaneous coronary intervention (including balloon angioplasty and stent implantation) * the stent diameter of des-isr is 2.5mm to 4.0mm * target lesion length \< 30mm * target lesion stenosis ≥ 70% diameter stenosis on visual assessment, or ≥ 50% diameter stenosis and with evidence of myocardial ischaemia ischemic exclusion criteria: * patients with acute myocardial infarction with 1 week * patients with evidence of extensive thrombosis in the target vessel * patients with left main coronary artery disease * patients with cardiogenic shock, left ventricular ejection fraction \< 40%,significant renal dysfunction and severe heart valve disease * patients who had cerebral stroke within 6 months before pci * patients with a life expectancy \< 1 year * patients not able to adhere to follow-up visits
french prospective observational study in patients eligible for systemic therapy for atopic dermatitis (ad)

Conditions: Atopic Dermatitis

Summary: the objective of the study is to describe the therapeutic management of patients more than or equal to 18 years old eligible for systemic therapy or treated by systemic therapy for atopic dermatitis (ad). this study will be proposed to a sample of french dermatologists experienced in the management of ad, practicing in hospital centers and/or office-based dermatologists. the study will be conducted in real conditions of practice, systemic treatment decisions will be taken at the sole initiative of the participating physician irrespective of the patient enrollment decision. each patient will be followed-up in routine care setting for 1 year.


Eligibility criteria:
inclusion criteria: * signed informed consent form. * patient with moderate to severe ad according to the investigator's judgment and 1. patient eligible to systemic treatment as atopic dermatitis control tool (adct) more than or equal to (≥) 7 and/or use topical corticosteroids (tcs) more than (\>) 90 gram (g)/month and/or tcs are not advisable. or 2. patient currently under systemic treatment. * able to understand and complete study-related questionnaires. exclusion criteria: * any condition that, in the opinion of the investigator, may interfere with patient's ability to participate in the study, such as short life expectancy, substance abuse, severe cognitive impairment, or other comorbidities that can predictably prevent the patient from adequately completing, as per routine care, the schedule of visits and assessments * patient receiving systemic therapy only for a disease other than ad. * patient participating in any interventional clinical trial at the time of enrolment. * patient is under tutorship or curatorship; patient under safeguard of justice or deprived of his/her liberty by an administrative or court decision
corticosteroid treatment for community-acquired pneumonia - the step trial

Conditions: Community-acquired Pneumonia

Summary: background: an intact hypothalami-pituitary-adrenal (hpa) axis with an effective intracellular anti-inflammatory activity of glucocorticoids is indispensable for host survival during stress upon exposure to an infectious agent. community-acquired pneumonia (cap) is characterized by significant mortality and increased circulating inflammatory cytokines. despite adequate antimicrobial therapy mortality rates for cap have not changed over several decades. the use of corticosteroids in patients with cap is inconclusive. study aim: to compare a 7 days treatment with prednisone and placebo in patients with community-acquired pneumonia with respect to time to clinical stability. study hypothesis: the investigators hypothesize that use of corticosteroids will lead to a 25% relative risk reduction for death and clinical instability. study type: randomized double blind intervention study patients: 800 patients with community-acquired pneumonia


Eligibility criteria:
inclusion criteria: 1. patients 18 years of age or older admitted for hospitalization from the community or a nursing home with cap. 2. cap will be defined by a new infiltrate on chest radiograph and the presence of one or several of the following acute respiratory signs or symptoms: * cough * sputum production * dyspnea * core body temperature \>38.0° c * auscultatory findings of abnormal breath sounds and rales * leukocyte count \>10 or \<4 x 109 cells l-1 (1) exclusion criteria: 1. patients or family members unable to give written informed consent, e.g. with severe dementia. 2. patients with active intravenous drug use. 3. severe immunosuppression (e.g. patients infected with human immunodeficiency virus infection and a cd4 count below 350 x 109/l, patients on immunosuppressive therapy after solid organ transplantation and neutropenic patients with neutrophil count \< 500 x 109/l and patients under chemotherapy with neutrophils 500-1000 x 109/l with an expected decrease to values \< 500 x 109/l); patients with cystic fibrosis as well as patients with active tuberculosis. 4. patients with acute burn injury 5. patients with acute gastrointestinal bleeding within 3 months of the current hospitalization 6. patients with an acute concomitant condition requiring more than 0.5mg/kg/d prednisone equivalent 7. pregnancy or breast feeding 8. patients with known adrenal insufficiency

Keywords: pneumonia corticosteroids clinical stability
temozolomide in treating women with advanced breast cancer

Conditions: Breast Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. purpose: phase ii trial to study the effectiveness of temozolomide in treating women who have advanced breast cancer.

objectives: i. assess the therapeutic activity of temozolomide in terms of tumor response, progression free and overall survival in women with advanced breast cancer. ii. assess the extent of atase depletion and dna methylation in the peripheral blood of these patients undergoing this regimen and investigate the relationship between these parameters and tumor response. outline: patients receive oral temozolomide every 4 hours for a total of 5 doses. treatment continues every 28 days for a minimum of 2 courses and a maximum of 1 year in the absence of unacceptable toxicity or disease progression. patients are followed at 30 days, and then every 2 months thereafter. projected accrual: a total of 14-30 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: histologically proven advanced carcinoma of the breast with documented progression on first line chemotherapy measurable disease hormone receptor status: not specified patient characteristics: age: 18 and over sex: female menopausal status: not specified performance status: not specified life expectancy: not specified hematopoietic: absolute neutrophil count at least 1,500/mm3 platelet count at least 100,000/mm3 hemoglobin at least 10 g/dl hepatic: bilirubin less than 1.5 times upper limit of normal (uln) ast no greater than 3 times uln alkaline phosphatase less than 2 times uln unless arising from bone renal: creatinine less than 1.5 times uln other: not pregnant or nursing negative pregnancy test fertile patients must use effective contraception no other clinically significant disease that would interfere with study evaluations no uncontrolled vomiting that would preclude administration of oral medications hiv negative prior concurrent therapy: biologic therapy: at least 4 weeks since prior biologic therapy and recovered chemotherapy: see disease characteristics at least 4 weeks since prior chemotherapy and recovered endocrine therapy: not specified radiotherapy: recovered from prior radiotherapy surgery: recovered from prior surgery other: no other concurrent experimental drugs

Keywords: stage iv breast cancer stage iiia breast cancer recurrent breast cancer stage iiib breast cancer
efficacy study of methotrexate to treat sarcoid-associated uveitis

Conditions: Sarcoid-associated Uveitis; Ocular Sarcoidosis; Macular Edema

Summary: the purpose of this study is to determine whether methotrexate is a effective corticosteroid sparing agent in the treatment of sarcoid-associated uveitis.

macular oedema remains a significant cause of blindness. corticosteroids are effective in the treatment of sarcoid-associated macular oedema but more than 50% of relapses occur when corticosteroids are tapered. methotrexate (mtx) at low dose has been shown to be an effective and safe steroid-sparing agent for lung sarcoidosis and compilation of reported small series of patients with sarcoid-associated uveitis suggest that only 25% of relapses could be achieved with low dose mtx. we decide therefore to test the clinical efficacy of mtx in sarcoid-associated uveitis.

Eligibility criteria:
inclusion criteria: * patients over 18 years old * provided written consent for participation in the trial prior to any study-specific procedures or requirements * posterior uveitis or panuveitis associated with macular oedema defined as increased macular thickness (more than 250 mm assessed by stratus td-oct or 300 mm with cirrus sd-oct ) and/or the presence of cystoid spaces in the macula, and the absence of epiretinal membranes. * patient with oral contraception * posterior uveitis or panuveitis associated with macular oedema * patients with histologically proven sarcoidosis or a presumed sarcoidosis. in case of a non caseating granuloma in biopsy tissues, the patients with presumed sarcoidosis meet at least 2 of the 4 following criteria: typical changes on chest radiography and computed tomography; predominantly cd4 lymphocytosis in bronchoalveolar lavage (bal) fluid; elevated serum ace levels; elevated gallium or 5 fluorodeoxyglucose uptake exclusion criteria: * patients who do not fulfill the inclusion criteria * other causes of uveitis * extra ophthalmologic manifestations of sarcoidosis justifying corticosteroids * patients previously treated with immunosuppressive agents or corticosteroids of more than 10 mg daily over 15 days. * patients with life-threatening conditions * chronic hepatopathy or renal failure * uncontrolled diabetes mellitus

Keywords: sarcoid-associated uveitis macular oedema methotrexate conventional corticosteroids sparing agent.
peripheral intravenous puncture guided by vascular ultrasound

Conditions: Intravenous Puncture Assertivity; Intravenous Puncture Guided by Vascular Ultrasound; Intravenous Therapy Complications

Summary: this research, aimed to verify whether the use of vascular ultrasonography (vus) could lead to better results in the peripheral venous access implementation in children. objectives: to compare, regardless of the number of venous puncture attempts, peripheral venous access obtained in children, according to vus use or traditional method for peripheral intravenous catheter (pic) insertion; assertiveness in the use of pic in children, defined as success in the first attempt of puncture and pic withdrawal according to release of treatment, related to vus or traditional method and to describe the influence of vus on pic dwell time and development of local complications related to the use of intravenous therapy in children.

clinical, randomized and controlled trial, conducted in a pediatric surgery ward of a university hospital in são paulo. data collection occurred from february 26th, 2007 to july 07th, 2008, after ethical merits of research approval. the sample comprised 382 venous puncture randomly allocated in the experimental group (eg), venous puncture guided by vus, or in the control group (cg), traditional method of venous puncture. variables related to children, intravenous therapy and professional characterization were collected. the dependent variables included the obtainment of peripheral venous access, the assertiveness, the catheter dwell time and the occurrence of local complications. for the statistical analysis were applied the pearson chi-square, fisher's exact, generalization of fisher's exact, mann-whitney, likelihood ratio and prevalence ratio (significance level of 5%).

Eligibility criteria:
inclusion criteria: * children submitted to intravenous therapy exclusion criteria: * adults

Keywords: pediatric nursing peripheral catheterization ultrasonics intravenous infusions
tele-rehabilitation pilot evaluation study

Conditions: Fractures, Bone; Stroke; Lower Limb Joint Replacement (Hip or Knee); Lower Limb Amputation; Pneumonia; Fall; Deconditioning; Musculoskeletal Conditions (e.g., Tendinitis, Capsulitis)

Summary: a proof of concept randomized controlled trial (rct) only evaluated the national university of singapore's (nus) t-rehab tele-rehabilitation (tr) system at a home setting where rehabilitation was provided on an individual level. the previous rct was also limited to stroke patients. in addition to stroke, there are many other conditions (such as fractures, lower limb joint replacement, musculoskeletal conditions) require and benefit from rehabilitation. the primary aims of the pilot evaluation study are: (i) to document patient adherence to tr, compared to usual care (ii) to estimate the extent to which tr improves functional status, compared to usual care and (iii) to estimate the cost effectiveness of tr, compared to usual care in eight different health conditions in singapore.

this is a 12-week quasi-experimental trial of a tele-rehabilitation program involving seven sites and up to 600 adults in singapore.

Eligibility criteria:
inclusion criteria: * at least 21 years of age * admitted into an inpatient or outpatient rehabilitation unit, nursing home or day care centre for an acute or chronic disability * deemed by any members of the multi-disciplinary rehabilitation team to potentially able to safely receive and benefit from rehabilitation post-discharge * cognitively able to understand and follow instructions (the abbreviated mental test's score of 6 or above (out of 10). exclusion criteria: * patients with previous seizure episodes * patients with limb musculoskeletal pain of at least moderate intensity (visual analogue scale \> 6 out of 10) * patients with pacemakers.
a study of tarceva (erlotinib) in patients with locally advanced or metastatic non-small cell lung cancer who present egfr mutations

Conditions: Non-Small Cell Lung Cancer

Summary: this single arm, open-label study will assess the efficacy and safety of tarceva (erlotinib) in patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor (egfr) mutations. patients will receive tarceva at a dose of 150 mg daily orally until disease progression or unacceptable toxicity occurs.


Eligibility criteria:
inclusion criteria: * adult patients, \>/=18 years of age * locally advanced or metastatic (stage iii/iv) non-small cell lung cancer with egfr mutations * measurable disease according to recist criteria * ecog performance status 0-2 * adequate haematological, renal and liver function exclusion criteria: * previous chemotherapy or therapy against egfr for metastatic disease * history of another malignancy, except for in situ carcinoma of the cervix, adequately treated basal cell skin carcinoma, or radically treated prostate carcinoma with good prognosis * symptomatic cerebral metastases * pre-existing parenchymal lung disease such as pulmonary fibrosis * concomitant use of coumarins
the effect of oral hygiene and full mouth scaling on metabolic control in patients with type ii diabetes

Conditions: Gingival Scaling; Metabolic Control

Summary: the aim of the study is to evaluate the effect of non-surgical periodontal therapy, consisting of oral hygiene instruction, full mouth scaling and an antimicrobial rinse on the metabolic control of chronic periodontitis patients with type ii diabetes mellitus.


Eligibility criteria:
inclusion criteria: 1. age 25- 75 years; 2. type 2 diabetes; 3. chronic periodontitis with 2 or more teeth with cal≥6mm and one site with a pd≥5mm ("established periodontitis")16 exclusion criteria: 1. periodontal treatment within the last 3 months 2. the use of antibiotics within the last 4 weeks 3. pregnancy or the intention to be pregnant in the next 4 months

Keywords: he effect of gingival scaling on metabolic control